Embargoed to 2301 Monday October 30
Taking aspirin may have a protective effect against a number of cancers, a new study suggests.
A trial involving more than 600,000 people found that long-term aspirin use appeared to reduce a person's risk of a number of digestive cancers as well as leukaemia, lung and prostate cancer.
The study, which is to be presented to the United European Gastroenterology (UEG) Week meeting in Barcelona, saw researchers compare cancer incidence among non-aspirin users and people who had been prescribed the drug for at least six months.
Researchers analysed data from all public hospitals in Hong Kong to compare information on 206,295 aspirin users - with an average of taking the medication for 7.7 years - and 412,589 non-aspirin users.
Patients were followed up for up to 14 years. Overall, 16% of people developed cancer.
Researchers found that long-term used of aspirin carried a "significant reduction" in the incidence of major gastrointestinal cancers.
Aspirin users were 47% less likely to have been diagnosed with cancers of the liver or oesophagus.
Experts also found significant reductions in the rate of stomach cancer, pancreatic cancer and bowel cancer with 38%, 34%, 24% reductions in incidence respectively among those who took the drug compared to non-aspirin users.
They also assessed cancers outside of the digestive system and found significant reductions in leukaemia, lung and prostate cancers among aspirin users.
Long-term aspirin users were 14% less likely to have developed prostate cancer, 24% less likely to have leukaemia and had a 35% reduced incidence of lung cancer.
But the authors did not find a protective effect for breast, bladder or kidney cancers.
"The findings demonstrate that the long-term use of aspirin can reduce the risk of developing many major cancers," said lead researcher Professor Kelvin Tsoi from the Chinese University of Hong Kong.
"What should be noted is the significance of the results for cancers within the digestive tract, where the reductions in cancer incidence were all very substantial, especially for liver and oesophageal cancer."
ends
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here